238 related articles for article (PubMed ID: 8391952)
1. TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy.
Maini RN; Brennan FM; Williams R; Chu CQ; Cope AP; Gibbons D; Elliott M; Feldmann M
Clin Exp Rheumatol; 1993; 11 Suppl 8():S173-5. PubMed ID: 8391952
[TBL] [Abstract][Full Text] [Related]
2. Targeting TNF alpha for the therapy of rheumatoid arthritis.
Maini RN; Elliott M; Brennan FM; Williams RO; Feldmann M
Clin Exp Rheumatol; 1994; 12 Suppl 11():S63-6. PubMed ID: 7768056
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA).
Maini RN; Elliott MJ; Brennan FM; Feldmann M
Clin Exp Immunol; 1995 Aug; 101(2):207-12. PubMed ID: 7648705
[TBL] [Abstract][Full Text] [Related]
4. The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis.
Camussi G; Lupia E
Drugs; 1998 May; 55(5):613-20. PubMed ID: 9585859
[TBL] [Abstract][Full Text] [Related]
5. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha.
Deleuran BW; Chu CQ; Field M; Brennan FM; Mitchell T; Feldmann M; Maini RN
Arthritis Rheum; 1992 Oct; 35(10):1170-8. PubMed ID: 1329775
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease.
Maini RN; Elliott MJ; Brennan FM; Williams RO; Chu CQ; Paleolog E; Charles PJ; Taylor PC; Feldmann M
Immunol Rev; 1995 Apr; 144():195-223. PubMed ID: 7590814
[TBL] [Abstract][Full Text] [Related]
7. New tumor necrosis factor-alpha biologic therapies for rheumatoid arthritis.
Breedveld F
Eur Cytokine Netw; 1998 Sep; 9(3):233-8. PubMed ID: 9831171
[TBL] [Abstract][Full Text] [Related]
8. A 7-day oral treatment of patients with active rheumatoid arthritis using the prostacyclin analog iloprost: cytokine modulation, safety, and clinical effects.
Gao IK; Scholz P; Boehme MW; Norden C; Lemmel EM
Rheumatol Int; 2002 Jun; 22(2):45-51. PubMed ID: 12070674
[TBL] [Abstract][Full Text] [Related]
9. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation.
Joosten LA; Helsen MM; Saxne T; van De Loo FA; Heinegard D; van Den Berg WB
J Immunol; 1999 Nov; 163(9):5049-55. PubMed ID: 10528210
[TBL] [Abstract][Full Text] [Related]
10. Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints.
Brennan FM; Gibbons DL; Mitchell T; Cope AP; Maini RN; Feldmann M
Eur J Immunol; 1992 Jul; 22(7):1907-12. PubMed ID: 1320571
[TBL] [Abstract][Full Text] [Related]
11. The role of cytokines in osteoarthritis pathophysiology.
Fernandes JC; Martel-Pelletier J; Pelletier JP
Biorheology; 2002; 39(1-2):237-46. PubMed ID: 12082286
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.
Williams RO; Feldmann M; Maini RN
Proc Natl Acad Sci U S A; 1992 Oct; 89(20):9784-8. PubMed ID: 1409699
[TBL] [Abstract][Full Text] [Related]
13. p55 and p75 tumor necrosis factor receptors are expressed and mediate common functions in synovial fibroblasts and other fibroblasts.
Butler DM; Feldmann M; Di Padova F; Brennan FM
Eur Cytokine Netw; 1994; 5(5):441-8. PubMed ID: 7880974
[TBL] [Abstract][Full Text] [Related]
14. [TNF inhibitors: a new therapeutic perspective in chronic inflammatory diseases in rheumatology?].
Fenner H
Z Rheumatol; 1995; 54(3):158-64. PubMed ID: 7660686
[TBL] [Abstract][Full Text] [Related]
15. [Paradigm shift in the treatment of rheumatoid arthritis by biologics].
Tanaka Y
Rinsho Byori; 2008 Apr; 56(4):309-15. PubMed ID: 18516965
[TBL] [Abstract][Full Text] [Related]
16. The role of cytokines in the pathogenesis of rheumatoid arthritis.
Feldmann M; Maini RN
Rheumatology (Oxford); 1999 Nov; 38 Suppl 2():3-7. PubMed ID: 10646481
[TBL] [Abstract][Full Text] [Related]
17. Cytokine expression and networks in rheumatoid arthritis: rationale for anti-TNF alpha antibody therapy and its mechanism of action.
Feldmann M; Brennan FM; Williams RO; Elliott MJ; Maini RN
J Inflamm; 1995-1996; 47(1-2):90-6. PubMed ID: 8913935
[TBL] [Abstract][Full Text] [Related]
18. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
19. TNF alpha as a therapeutic target in rheumatoid arthritis.
Feldmann M; Brennan FM; Elliott M; Katsikis P; Maini RN
Circ Shock; 1994 Aug; 43(4):179-84. PubMed ID: 7895323
[TBL] [Abstract][Full Text] [Related]
20. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion.
Woolley DE; Tetlow LC
Arthritis Res; 2000; 2(1):65-74. PubMed ID: 11219391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
